Alzheimer’s Researchers Identify Biomarkers of Response to Anavex 2-73 Treatment

Alzheimer’s Researchers Identify Biomarkers of Response to Anavex 2-73 Treatment
Researchers have identified two biomarkers that could help determine which Alzheimer’s disease patients can benefit from Anavex 2-73 treatment. The results were reported at the 2018 Alzheimer’s Association International Conference (AAIC) in Chicago. The study, “Systematic Processing of Full Genomic Analysis of ANAVEX®2-73 Phase 2a Alzheimer’s Disease Study Identifies Biomarkers Enabling a Precision Medicine Approach,” was presented by Harald Hampel, the study’s first author and AXA Research Fund and Sorbonne University Excellence Chair at Sorbonne University in Paris. Anavex 2-73, developed by Anavex Life Sciences, is an investigational therapy with the potential to modify the course of Alzheimer’s disease instead of acting on symptoms alone. It binds to and activates the Sigma-1 receptor (SIGMAR1), known to have neuroprotective effects, resulting in reduced neuroinflammation, accumulation of beta amyloid and tau proteins, and oxidative stress. All are involved in Alzheimer’s disease and other neurodegenerative disorders. Results from a randomized, open-label, Phase 2a study (NCT02244541) showed that one-year of treatment with Anavex 2-73 was safe and prevented further cognitive decline in 32 people with mild to moderate Alzheimer’s. From those participants, 21 agreed to move to a two-year open-label Phase 2 extension study (NCT02756858) where they would continue to receive Anavex 2-73. The study aimed to evaluate the therapy’s long-term safety and therapeutic benefits. Researchers conducted a detailed analysis on the entire DNA and RNA — the molecule produced from DNA that contains the instructions to produce a protein — of these patients to find biomarkers of response to Anavex 2-73. After analyzing 33,311 genes a
Subscribe or to access all post and page content.